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Chronic kidney disease (CKD) is characterized by gradual decrease in renal function 
and affects more than 10% of the general population. CKD has the potential to lead 
to end stage renal disease but it is already associated with cardiovascular 
complications at earlier stages of the disease process. Diabetes and hypertension 
are among the main causes of CKD [1;2], with age, smoking and obesity being 
important pathophysiological co-factors. A further independent risk factor for CKD 
and acute kidney injury (AKI) is HIV infection [3-5]. The United States Renal Data 
System database reported a risk of ESRD by 50-fold higher in HIV-infected than in 
non-HIV infected [6].  
In general there is no cure for CKD. Once CKD is established the pragmatic 
therapeutic goal in clinical practice is prevention of further progression. It is clear, 
however, that a primary preventative approach with treatment before the onset of 
CKD would be much more attractive. Approaches to apply primary preventative 
intervention to all patients at presumed risk, e.g. by treating all patients with diabetes 
and normoalbuminuria, are hampered by an unfavourable balance between a 
possible preventative effect on CKD and adverse events related to the medication 
[7]. A targeted preventative approach in those at highest risk of developing CKD has 
the potential to overcome these problems. 
Such personalised primary prevention requires the availability of precise biomarkers 
of CKD. Decreased glomerular filtration rate and presence of albuminuria are 
established markers of CKD. However, these markers occur relatively late in the 
disease process are not directly associated with the underlying molecular 
pathophysiology but rather a result of the compromised kidney function. More 
recently, urinary biomarkers emerged as a valid approach to detect CKD, and to 
predict development and progression of CKD [8-10]. Urine is considered an excellent 
source of biomarkers for CKD as products from the kidney are directly “deposited” in 
urine. However, it appears that single biomarkers cannot fully describe changes in 
renal function related to the complex pathophysiology of CKD. As a consequence, 
the concept of a multi-marker approach has been advocated for CKD [11].  
The recent report by Scherzer et al. [12] adds to the number of studies investigating 
early urinary biomarkers for incident CKD and again highlights the benefit of multiple 
urinary biomarkers to predict CKD progression. The authors measured 8 urine 
biomarkers previously associated with incidence of CKD in 902 HIV-infected women 
as part of the Women’s Interagency HIV study [13-15]. NAG, KIM-1, alpha-1 
microglobulin (α1m), IL-18, NGAL, ACR, L-FABP, and AAG were selected as 
candidate biomarkers. Among these biomarkers NAG, KIM-1, alpha-1 microglobulin 
displayed the highest combined predictive value and divided the cohort into three 
clusters, with cluster 1 being the lowest and cluster 3 being the highest risk group for 
CKD after multivariate adjustment for traditional kidney and HIV risk factors. Main 
results were: 
a) In the highest risk cluster women were older, often African American and 
hypertensive. 
b) After multivariate adjustment for traditional kidney and HIV risk factors, clusters 2 
and 3 displayed the higher risk of CKD, compared to the cluster 1. 
c) Cluster 3 was associated with a more than 2-fold greater risk of mortality compared 
to cluster 1. 
d) The addition of three selected biomarkers (NAG, KIM-1, alpha-1 microglobulin) to the 
model based on traditional kidney and HIV risk factors identified an additional 15% of 
patients at high risk, however 7.9% of patients were inappropriately reclassified as 
lower risk patients. 
e) Each biomarker was individually associated with an increased risk of CKD and 
mortality, after adjustment for traditional and HIV-related risk factors. 
Participants classified as high risk had more comorbidities and worse HIV-related 
characteristics at baseline. Relative to those who were in the low risk category, this 
high risk cluster had 4-fold higher rates of incident CKD (50% vs. 13%) and all-cause 
mortality (41% vs. 10%). Although the new cluster variable only moderately improved 
model discrimination for CKD risk compared with a model containing traditional risk 
factors, the cluster was independently associated with each study outcome. The 
authors acknowledge that the data have not yet been validated in an external cohort, 
but envision that clinicians will ultimately be able to use a biomarker panel to 
determine the level of risk (low, moderate, or high) for CKD and mortality of an 
individual HIV-infected patient. 
 
While the report highlights the potential of such an approach, it leaves several 
questions open that are to be answered in future studies. Among them is the 
question if three biomarkers suffice to describe, assess and predict the outcome of a 
heterogeneous disease such as CKD, and HIV-related CKD is in no way a uniform 
and homogenous condition. While in the data presented the tested additional 
biomarkers did not add significant value, this may also be due to limited power. If 
strength is in numbers, the addition of further biomarkers may improve the stability of 
the classifier, and increase the possibility to better define a disease [16]. Even 
though multiple biomarkers have been employed by Scherzer et al., their value 
needs to be assessed in an independent set. Only such validation will ensure that 
the biomarkers meet the patients' needs. Given the fairly large dataset, the study 
may also provide an opportunity to investigate performance of different algorithms to 
be employed when combining multiple biomarkers. The choice by the authors was a 
very successful one, but others like e.g. artificial neural networks or support vector 
machines may provide even more power [17]. 
As also outlined by the authors, only markers of proximal tubular injury and function, 
with the exception of ACR (glomerular injury) and NGAL (maybe distal or mixed 
proximal/distal), were assessed in this study. Incorporation of markers that identify 
other aspects of nephron function and injury will probably allow even better 
assessment of risk. 
The study included only women, and little is known about associations of urine 
biomarkers with kidney outcomes in HIV-infected men. Furthermore, racial 
differences in CKD incidence and progression to ESRD in HIV-infected individuals 
are well known [18]. Indeed, HIV-associated nephropathy (HIVAN) appears to 
progress more aggressively to ESRD in those of African descent [19] [20]. Also in 
the present study, Scherzer at al. confirmed the higher risk of African American 
Women. Racial differences are highly relevant for the assessment of such complex 
disease and must be taken into account to overcome possible bias in the results. 
 
An important conclusion to be drawn from the present study is that a combination of 
urinary biomarkers is of value in the assessment of renal diseases in HIV-infected 
individuals. The use of a large set of patients allowed a better stratification of 
different level of risk groups. It is, however, equally important to stress that certain 
aspects (e.g. appropriate control groups, adjustment for variance and confirmation in 
validation test) need to be assessed before translation of such biomarkers into 
clinical practice. 
The study adds significant additional evidence supporting the hypothesis that 
multiple urinary biomarkers, in combination, enable early detection/prognosis of 
onset and progression of CKD. The findings, in combination with the current 
knowledge, raise several highly relevant questions: 
1) Which biomarkers should be used, and how should they be combined? A 
comparative study assessing the performance of the different biomarkers and 
algorithms seems urgently required. This was already proposed and also 
implemented for other clinical areas[21;22], and it appears high time that similar 
efforts are undertaken in CKD. 
2) What are the consequences of early detection? While interference with the 
RAAS may be a valid option in diabetic nephropathy, this may not necessarily apply 
to HIV-associated CKD. 
3) How to evaluate success of such a strategy? If the current dogma of many 
regulators, that success can only be demonstrated based on economic benefit or 
significant impact on hard endpoints, then these potentially highly beneficial 
developments will never be implemented to benefit patients. An answer to this 
question can likely only be found on a political level. 
Collectively, the demonstration of the value of urinary protein biomarker in the early 
detection/prognosis of progression of CKD by Scherzer et al. in this issue of NDT 
[12], the recent indication by EMA to accept disease prevention as a relevant 
endpoint in a study in CKD [23], and the recent attempts to utilize molecular data to 
identify potential additional specific novel therapeutic targets in CKD [24] give rise to 
the enthusiastic hope that CKD can in fact be successfully addressed in the near 
future. A first approach in this direction appears to be the PRIORITY trial [25], where 
urinary biomarkers are employed for the early detection of diabetic nephropathy, and 
only those at highest risk for development of clinically overt CKD will be randomised 
to active preventative therapy. 
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